CortexID Suite^CortexID software has been developed to aid physicians in the evaluation of patient pathologies via assessment and quantification of PET brain scans. The software aids in the assessment of human brain PET scans enabling automated analysis through quantification of tracer uptake and comparison with the corresponding tracer uptake in normal subjects. The resulting quantification is presented using volumes of interest, voxel-based or 3D stereotactic surface projection maps of the brain. The package allows the user to generate information regarding relative changes in PET-FDG glucose metabolism and in PET brain amyloid load between a subject's images and a normal database, which may be the result of brain neurodegeneration.* Trademark of General Electric Company^ 510(k) pending at FDA. Not available for sale in the United States. Not for sale in all regions.
Personalized Care From Disease Detection Through Treatment Assessment Enabled With GE Healthcare's Discovery IQ
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts